Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109


Targeting the p53 pathway in retinoblastoma with subconjunctival Nutlin-3a.

Brennan RC, Federico S, Bradley C, Zhang J, Flores-Otero J, Wilson M, Stewart C, Zhu F, Guy K, Dyer MA.

Cancer Res. 2011 Jun 15;71(12):4205-13. doi: 10.1158/0008-5472.CAN-11-0058. Epub 2011 Apr 22.


Small molecule inhibition of HDM2 leads to p53-mediated cell death in retinoblastoma cells.

Elison JR, Cobrinik D, Claros N, Abramson DH, Lee TC.

Arch Ophthalmol. 2006 Sep;124(9):1269-75.


Activation of the p53 pathway by the MDM2 inhibitor nutlin-3a overcomes BCL2 overexpression in a preclinical model of diffuse large B-cell lymphoma associated with t(14;18)(q32;q21).

Drakos E, Singh RR, Rassidakis GZ, Schlette E, Li J, Claret FX, Ford RJ Jr, Vega F, Medeiros LJ.

Leukemia. 2011 May;25(5):856-67. doi: 10.1038/leu.2011.28. Epub 2011 Mar 11.


Targeting MDM2 and MDMX in retinoblastoma.

Laurie NA, Shih CS, Dyer MA.

Curr Cancer Drug Targets. 2007 Nov;7(7):689-95. Review. Erratum in: Curr Cancer Drug Targets. 2008 Jun;8(4):341. Schin-Shih, Chie [corrected to Shih, Chie-Schin].


Reversal of P-glycoprotein-mediated multidrug resistance by the murine double minute 2 antagonist nutlin-3.

Michaelis M, Rothweiler F, Klassert D, von Deimling A, Weber K, Fehse B, Kammerer B, Doerr HW, Cinatl J Jr.

Cancer Res. 2009 Jan 15;69(2):416-21. doi: 10.1158/0008-5472.CAN-08-1856.


Targeted nutlin-3a loaded nanoparticles inhibiting p53-MDM2 interaction: novel strategy for breast cancer therapy.

Das M, Dilnawaz F, Sahoo SK.

Nanomedicine (Lond). 2011 Apr;6(3):489-507. doi: 10.2217/nnm.10.102.


Subconjunctival carboplatin and systemic topotecan treatment in preclinical models of retinoblastoma.

Nemeth KM, Federico S, Carcaboso AM, Shen Y, Schaiquevich P, Zhang J, Egorin M, Stewart C, Dyer MA.

Cancer. 2011 Jan 15;117(2):421-34. doi: 10.1002/cncr.25574. Epub 2010 Sep 3.


Antitumor activity of the selective MDM2 antagonist nutlin-3 against chemoresistant neuroblastoma with wild-type p53.

Van Maerken T, Ferdinande L, Taildeman J, Lambertz I, Yigit N, Vercruysse L, Rihani A, Michaelis M, Cinatl J Jr, Cuvelier CA, Marine JC, De Paepe A, Bracke M, Speleman F, Vandesompele J.

J Natl Cancer Inst. 2009 Nov 18;101(22):1562-74. doi: 10.1093/jnci/djp355. Epub 2009 Nov 10.


Whole-body physiologically based pharmacokinetic model for nutlin-3a in mice after intravenous and oral administration.

Zhang F, Tagen M, Throm S, Mallari J, Miller L, Guy RK, Dyer MA, Williams RT, Roussel MF, Nemeth K, Zhu F, Zhang J, Lu M, Panetta JC, Boulos N, Stewart CF.

Drug Metab Dispos. 2011 Jan;39(1):15-21. doi: 10.1124/dmd.110.035915. Epub 2010 Oct 14.


MDM2 inhibitor Nutlin-3a suppresses proliferation and promotes apoptosis in osteosarcoma cells.

Wang B, Fang L, Zhao H, Xiang T, Wang D.

Acta Biochim Biophys Sin (Shanghai). 2012 Aug;44(8):685-91. doi: 10.1093/abbs/gms053.


Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1.

Ambrosini G, Sambol EB, Carvajal D, Vassilev LT, Singer S, Schwartz GK.

Oncogene. 2007 May 24;26(24):3473-81. Epub 2006 Dec 4.


Topotecan combination chemotherapy in two new rodent models of retinoblastoma.

Laurie NA, Gray JK, Zhang J, Leggas M, Relling M, Egorin M, Stewart C, Dyer MA.

Clin Cancer Res. 2005 Oct 15;11(20):7569-78. Erratum in: Clin Cancer Res. 2009 May 15;15(10):3643.


E2F-1 transcriptional activity is a critical determinant of Mdm2 antagonist-induced apoptosis in human tumor cell lines.

Kitagawa M, Aonuma M, Lee SH, Fukutake S, McCormick F.

Oncogene. 2008 Sep 11;27(40):5303-14. doi: 10.1038/onc.2008.164. Epub 2008 Jun 2.


MDM2 antagonist Nutlin-3a potentiates antitumour activity of cytotoxic drugs in sarcoma cell lines.

Ohnstad HO, Paulsen EB, Noordhuis P, Berg M, Lothe RA, Vassilev LT, Myklebost O.

BMC Cancer. 2011 May 30;11:211:1-11. doi: 10.1186/1471-2407-11-211.


[TP53 and RB tumor suppressor pathways collaborate in retinoblastoma genesis].

Ayrault O, Zindy F, Roussel MF.

Med Sci (Paris). 2007 Apr;23(4):356-8. French. No abstract available.


Induction of p53-dependent senescence by the MDM2 antagonist nutlin-3a in mouse cells of fibroblast origin.

Efeyan A, Ortega-Molina A, Velasco-Miguel S, Herranz D, Vassilev LT, Serrano M.

Cancer Res. 2007 Aug 1;67(15):7350-7.


Activation of p53 by nutlin-3a induces apoptosis and cellular senescence in human glioblastoma multiforme.

Villalonga-Planells R, Coll-Mulet L, Martínez-Soler F, Castaño E, Acebes JJ, Giménez-Bonafé P, Gil J, Tortosa A.

PLoS One. 2011 Apr 5;6(4):e18588. doi: 10.1371/journal.pone.0018588.


Effect of MDM2 and vascular endothelial growth factor inhibition on tumor angiogenesis and metastasis in neuroblastoma.

Patterson DM, Gao D, Trahan DN, Johnson BA, Ludwig A, Barbieri E, Chen Z, Diaz-Miron J, Vassilev L, Shohet JM, Kim ES.

Angiogenesis. 2011 Sep;14(3):255-66. doi: 10.1007/s10456-011-9210-8. Epub 2011 Apr 12.


In vitro and in silico studies of MDM2/MDMX isoforms predict Nutlin-3A sensitivity in well/de-differentiated liposarcomas.

Bozzi F, Conca E, Laurini E, Posocco P, Lo Sardo A, Jocollè G, Sanfilippo R, Gronchi A, Perrone F, Tamborini E, Pelosi G, Pierotti MA, Maestro R, Pricl S, Pilotti S.

Lab Invest. 2013 Nov;93(11):1232-40. doi: 10.1038/labinvest.2013.107. Epub 2013 Sep 9.

Items per page

Supplemental Content

Write to the Help Desk